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Abstract 
 
Background: Neonatal Abstinence Syndrome (NAS) is an anticipated effect of maternal 
drug use during pregnancy. Yet it remains a contested area of policy and practice. In this 
paper, we contribute to ongoing debates about the way NAS is understood and responded to, 
through different treatment regimes, or logics of care. Our analysis examines the role of risk 
and recovery discourses, and the way in which the bodies of women and babies are 
conceptualised within these. 
Methods: Qualitative interviews with 16 parents (9 mothers, 7 fathers) and four focus groups 
with 27 health and social care professionals based in Scotland. All the mothers were 
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prescribed opioid replacement therapy and parents were interviewed after their baby was 
born. Data collection explored understandings about the causes and consequences of NAS 
and experiences of preparing for, and caring for, a baby with NAS. Data were analysed using 
a narrative and discursive approach.  
Results: Parent and professional accounts simultaneously upheld and subverted logics of care 
which govern maternal drug use and the assessment and care of mother and baby. Despite 
acknowledging the unpredictability of NAS symptoms and the inability of the women who 
are opioid-dependent to prevent NAS, logics of care centred on ‘proving’ risk and recovery. 
Strategies appealed to the need for caution, intervening and control, and obscured alternative 
logics of care that focus on improving support for mother-infant dyads and the family as a 
whole. 
Conclusion: Differing notions of risk and recovery that govern maternal drug use, child 
welfare and family life both compel and trouble all logics of care. The contentious nature of 
NAS reflects wider socio-political and moral agendas that ultimately have little to do with 
meeting the needs of mothers and babies. Fundamental changes in the principles, quality and 
delivery of care could improve outcomes for families affected by NAS. 
 
Introduction 
Lupton (2012) argues that the bodies of infants are framed as inherently ‘vulnerable’ and ‘at 
risk’, a framing which contributes to the imperative that parents (particularly mothers) engage 
in “intense, anxious” surveillance of their infants. In this paper, we examine how this 
conceptualisation of the infant body as ‘at risk’ emerges in accounts of Neonatal Abstinence 
Syndrome (NAS), and how this surveillance is connected to wider systems which seek to 
regulate drug-using bodies (Fraser & valentine, 2008). We argue that the obligation to 
monitor and measure is particularly acute for the ‘vulnerable’ drug-exposed neonate, and this 
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has implications for the governance of mothers who are drug-dependent who gave rise to 
their infants’ ‘vulnerable’ condition. Lupton’s work addresses ‘routine’ antenatal and 
postnatal care, and she refers to parental (and professional) monitoring of ‘vulnerable’ infant 
bodies within the context of a normative ‘risk culture’, whereby any potential risks should be 
minimised: we show how this is implicated in accounts of NAS. 
NAS is the most frequently cited ‘complication’ of maternal drug use during pregnancy –
portrayed as a risk to the newborn baby, the mother-infant relationship, caregiving, child 
development and child welfare (McQueen, Murphy-Oikonen, & Desaulniers, 2015). NAS 
refers to a constellation of drug withdrawal symptoms identified in babies born to mothers 
who have used drugs of dependence during pregnancy, notably opioids (Hudak, et al., 2012). 
Not all infants develop symptoms but those who do normally display signs within the first 
few days after birth. The condition is relatively short-lived, lasting from several days to 
weeks, and symptoms vary considerably in onset, severity and duration (American College of 
Obstetrics and Gynecologists, 2017). Symptoms primarily involve the gastrointestinal, 
autonomic and central nervous system, resulting in a neonate who can be difficult to feed, 
settle and console (Hudak et al 2012) – see Table 1.  
Table 1: Symptoms of severe NAS 
Central Nervous 
system 
Irritability (high-pitched/excessive crying) 
Increased wakefulness/sleep disturbance 
Tight muscle tone 
Hyperactive reflexes 
Excoriations of skin from excessive movements 
Frequent yawning and sneezing  
Rarely seizures 
Autonomic 
nervous system 
 
Hypersensitivity to stimuli 
Tremors 
Fever 
Increased sweating 
Stuffy nose 
Mottling 
Unstable temperature 
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Gastrointestinal 
system 
 
Poor feeding 
Uncoordinated suck reflex/constant sucking 
Vomiting 
Diarrhoea 
Dehydration 
Poor weight gain or weight loss 
 
Although NAS is an entirely “expected and treatable condition” (ACOG 2017: p.6), it 
remains an emotive and highly contentious subject (Terplan & Minkoff, 2017), and is in itself 
a contested diagnostic label. Some countries, especially post-Soviet nations, do not formally 
recognise NAS (WHO, 2014). Across the globe and within individual countries, there are 
contradictory approaches to identifying, measuring and treating NAS (Kelly, et al., 2016; 
O'Grady, Hopewell, & White, 2009); and while NAS is associated with maternal use of 
drugs, other factors are implicated in symptom severity in highly complex ways. For instance, 
the correlation between maternal opioid dose (e.g., methadone) and neonatal symptom 
severity is not straightforward (Cleary, et al., 2010). Some babies born to mothers on high 
doses of methadone exhibit minimal signs of withdrawal, while others born to mothers on 
low doses may show more significant signs. Symptoms vary depending on numerous other 
variables, including: genetic factors; type of drug/s used by the mother (including tobacco 
and SSRIs); maternal metabolism and net drug transfer across the placenta; placental 
metabolic rate; infant birth weight and gestational age; infant metabolism and excretion of the 
drug/s; as well as breastfeeding and the use of supportive comfort measures (Hudak, et al., 
2012; WHO, 2014). Consequently, symptoms cannot be accurately predicted at an individual, 
mother-infant dyad level (Kaltenbach, et al., 2012).  
NAS: attitudes and approaches to maternal drug use during pregnancy 
A key issue in clinical literature pertains to the care of pregnant women and whether or not 
NAS, or its worst manifestations, can be prevented. However, there is conflicting evidence 
and little consensus on this issue, as well as historical and ideological factors which continue 
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to plague practice. For example, the ‘choice’ of opioid replacement therapy (ORT) for 
mothers has evoked considerable debate, particularly in response to the recent MOTHER 
study (Jones, et al., 2008), which compared outcomes in babies born to mothers randomised 
to either buprenorphine or methadone during pregnancy. Buprenorphine resulted in better 
NAS outcomes than methadone, but the attrition rate in the buprenorphine treatment group 
was higher. Ensuing disputes about whether buprenorphine should be recommended as ‘the 
drug of choice’ for pregnant women highlighted tensions between whose body we should be 
caring about most and what ‘risks’ we should be prioritising – mothers or babies? (McCarthy, 
Leamon, Stenson, & Biles, 2008).  
Complicating matters, previous guidance on the care of pregnant women who are opioid-
dependent recommended reduction of methadone to ‘the lowest possible dose’ with some 
guidance proposing very low, sub-therapeutic levels (<40mgs/day) to avoid NAS (Wolff & 
Perez-Montejano, 2014). Although this guidance was superseded years ago because of 
mounting evidence against this advice, its legacy remains (Chandler, et al., 2013). Coupled 
with the resurgence of drug policies which promote ‘recovery’ (often assumed to mean 
‘abstinence’, or at least ‘proven’ drug reduction/stabilisation), current evidence and clinical 
guidelines on the use of optimal dose, maintenance ORT throughout pregnancy, has been 
adopted internationally but remains controversial (WHO, 2014).  
NAS: caregiving environments and parenting capacity 
NAS is frequently portrayed as a ‘risk factor’ for subsequent child abuse and neglect (De 
Bortoli, Coles, & Dolan, 2014). It is assumed that mothers and fathers who are drug-
dependent will be unable to respond appropriately to the needs of a newborn baby with NAS. 
Literature on maternal substance use draws attention to ‘chaotic’ lifestyles dominated by 
drug-seeking behaviour, ‘risky’ or suboptimal caregiving environments, and mothers’ lack of 
‘emotional availability’ and/or compromised ability to establish a secure attachment with 
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their infant (Hatzis, Dawe, Harnett, & Barlow, 2017). Fathers and/or male partners are 
portrayed as absent, uninvolved, aggressive, uncaring and/or unsupportive of mothers (De 
Bortoli, et al., 2014). Within a prevailing view that drug use is incompatible with being a 
good parent, mothers and fathers who are drug-dependent are typically characterised as unfit 
parents (Benoit, Magnus, Phillips, Marcellus, & Charbonneau, 2015; Whittaker, et al., 2016). 
Thus, care is orientated towards the requirement for parents, especially mothers, to ‘prove’ 
themselves worthy (and trustworthy) before they can be free of state intervention (including 
removal of their infant). Within such a context, the drug-exposed (‘poisoned’) body of the 
NAS infant becomes an ‘indicator of risk’ - of actual or potential harm (child abuse and 
neglect) - and abstinence becomes the idealised goal, with the production of ‘clean’ drug 
toxicology tests, a proxy measure of parenting capacity and being ‘a good enough parent’ 
(Chandler, et al., 2013). 
NAS: Models of Care  
With NAS, the inter-embodiment (Lupton 2012) of infant and caregiver is potentially 
disrupted, depending on the model of care in place in a given context. Current opinion 
remains divided on how best to care for infants and families affected by NAS (WHO 2014). 
The conceptualisation of maternal and neonatal bodies, the closeness or distance of the 
mother-infant dyad, is central to this. In clinical literature for instance, there is ongoing 
uncertainty regarding the effectiveness and long term consequences of pharmacological 
‘comforts’ to reduce NAS symptoms, and in many cases, clinical guidelines indicate the need 
for ‘special care’ in neonatal units (NNU) (Grim, Harrison, & Wilder, 2013; WHO, 2014). At 
one extreme, this includes having infants admitted to the NNU immediately following the 
birth or symptom onset, entirely separate from contact with the primary caregiver, and 
isolated in an attempt to minimise light, noise and other stimuli (Boyd, 1999). In contrast, a 
parallel body of literature argues that NAS babies can be cared for adequately in out-patient 
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settings and at home by the birth mother whenever possible, with the mother supported to 
‘room-in’ with her baby, provide ‘skin-to-skin’ contact, breastfeed, and provide supportive 
attachment-focused infant care (Abrahams, et al., 2007; Knopf, 2016; Kocherlakota, 2014). 
Within this approach, separation of mother and baby is proactively avoided and there is a 
distinct ‘low-interventionist’ (non-medicalising) approach.  
The wider context of NAS 
Studies which have explicitly addressed the wider social and cultural contexts of caring for 
NAS babies are sparse, though several ethnographic studies show fear of NAS, and stigma 
associated with the diagnosis, can affect treatment engagement of pregnant women (Boyd, 
1999; Klee, Jackson, & Lewis, 2002; Knight, 2015). These studies suggest babies who 
exhibit symptoms attributed to NAS are understood to be at greater risk of being removed 
from the mother. Some qualitative studies have examined neonatal nurses’ experiences of 
caring for NAS babies (e.g. Maguire, Webb, Passmore, & Cline, 2012; Murphy-Oikonen, 
Brownlee, Montelpare, & Gerlach, 2010) and report a fairly negative and conflicted picture, 
with staff struggling to engage positively with families, and problematic attitudes towards 
parents/mothers who are drug-dependent. Two studies (Atwood, et al., 2016; Cleveland & 
Gill, 2013) conducted in the USA, explored the views of parents, revealing low levels of 
parental education and preparation for NAS, inconsistent and contradictory approaches to 
care of mother and baby, heightened feelings of stigma, guilt and blame, and the importance 
of good quality relationships and communication with neonatal staff.  
Study aim and theoretical approach 
This study aimed to explore ‘logics of care’ (Mol, 2008) that govern pregnant women who 
use drugs and babies at risk of NAS in Scotland, UK. In this paper, we focus on ways in 
which risk and recovery are represented and responded to, within the context of maternal 
drug use, child welfare and family life. 
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Our analysis is informed by feminist, materialist and poststructuralist theories. While drawing 
on accounts of NAS, we attend to how these represent the “socio-material arrangements” 
through which NAS is produced (Fomiatti, Moore, & Fraser, 2017). This includes how 
parents’ account for interactions with services during and after pregnancy, and the particular 
‘logics of care’ which are refer to by parents and professionals. Mol’s (2008) logic of care 
refers to the complex ways in which ‘good’ healthcare is enacted. Her analysis contrasts this 
with a logic of choice, a logic she argues is erroneous, as it assumes the existence of rational, 
autonomous patients, and linear processes of evidence gathering and decision-making. A 
logic of care, Mol suggests, allows for consideration of the complex ways that healthcare can 
operate, dealing as it does with systems, relationships, practices, values, emotions, structures, 
technology and individual, sometimes ill, bodies which have diverse lives. In our usage of the 
concept, we view this as multiple, thus we consider logics of care. In this way, we examine 
the ways in which accounts of practices relating to NAS do orient around care (e.g., care of 
the baby, care of the mother/father, care of mother-infant dyad) but in different ways, and 
with different implications for different actors involved (e.g., mothers, fathers, infants, 
professionals). The focus of enquiry in this paper centres on exposing some of the different 
logics of care governing responses to NAS and how these are shaped by contested and 
contradictory understandings of risk and recovery. 
 
Methods 
Design 
Our paper draws on data generated in a qualitative study involving interviews with parents 
(mothers who are opioid-dependent and their partners) and focus groups with health and 
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social care practitioners who work with families affected by NAS. Ethical approval was 
granted by the local NHS Research Ethics Committee.  
Study setting 
The study was conducted in Scotland, UK, from December 2014 – August 2015, with 
participants drawn from a major city, and neighbouring towns. The area included community-
based addiction, maternity and child health services, two neonatal units (in separate 
hospitals), and a specialist multiagency home-visiting service for pregnant women who are 
drug-dependent. All the families in the study had access to ‘universal health care’ (e.g. GP, 
midwifery, child health and neonatal services) and specialist secondary health care (e.g. 
addiction treatment), free of charge, as part of the UK National Health Service (NHS). This 
includes Opioid Replacement Therapy (ORT) – usually methadone or buprenorphine - 
provided by either community-based addiction treatment services or the GP, with 
medications dispensed via local pharmacy.   
Parent participants and interviews 
We conducted in-depth semi-structured interviews with a purposive sample of 16 parents, 
including two single mothers and seven mother-father dyads (interviewed separately because 
of the highly sensitive and potentially emotive nature of the discussion). All the mothers were 
prescribed ORT and were recruited via community drug treatment, midwifery and child 
health services. Fathers/partners were invited to take part if the mother agreed to their 
involvement in the study. Parents were interviewed between two weeks and six months after 
the birth of their baby and were provided with a £20 gift voucher to cover out-of-pocket 
expenses. Interviews were conducted by [AC], lasted approximately 60-90 minutes, and 
explored understandings of NAS and experiences of caring for a baby at risk of NAS as well 
as topics related to the parents’ drug use and drug treatment, social and economic 
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circumstances, contextual features of their lives, and experiences engaging with health and 
social services during and after pregnancy, with a particular focus on NAS.  
A profile of parent participants is included in Table 2. Aged between 23 and 41, all but two 
had older children. In the majority of cases, older children were living elsewhere (foster care, 
kinship care, or with ex-partners). Thus, while all participants had custody of their most 
recent baby, six of the nine mothers (and one father) did not have parental responsibility for 
their older children. Fathers with older children described previous relationships where their 
ex-partner retained child custody and contact with these children was sporadic or absent. At 
the time of interview, all but one parent (a mother on maternity leave) were on various forms 
of welfare benefits. All parents were living in rented social housing, and many described 
recent experiences of housing insecurity or homelessness. 
Table 2: Profile of parents in study 
Pseudonym Age Family Drug use/history 
Joanne 34 Mike’s partner. 
Older child/ren in foster care 
Methadone prescription 
History of heroin and alcohol use 
Mike 41 Joanne’s partner. 
Older child/ren living with ex-partner 
Methadone prescription 
Hx Heroin  
 
Hayley 23 Liam’s partner. 
First child. 
Dihydrocodeine prescription 
Hx Heroin 
Liam 34 Hayley’s partner. 
Older child/ren living with ex-partner 
Dihydrocodeine prescription 
Hx Heroin and alcohol use 
Liz 35 Single mother. 
Older child/ren at home 
Methadone prescription 
Hx Heroin  
Kelly 36 Single mother. 
Older child/ren living at home and in 
kinship care 
Methadone prescription 
Hx Heroin 
Heather 40 Craig’s partner. 
Older child/ren in kinship care 
Methadone prescription 
Hx Benzodiazepine use 
Craig 40 Heather’s partner. 
Older child/ren in kinship care 
Methadone prescription 
Hx Heroin 
Shelley 35 Ryan’s partner. 
Older child/ren living at home 
Buprenorphine prescription 
Hx Heroin 
Ryan 36 Shelley’s partner. Methadone prescription 
Hx Heroin 
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Older child/ren living with partner 
and ex-partner 
Carla 31 Miles’ partner. 
Older child/ren in kinship care 
Methadone and diazepam prescription 
Hx Heroin 
Miles 32 Carla’s partner. 
First child 
Abstinent 
No history of drug use reported 
Eilidh 28 Stuart’s partner. 
Older child/ren with ex-partner 
Methadone and diazepam prescription 
Hx Heroin, Gabapentin,  
Stuart 38 Eilidh’s partner. 
Older child/ren with ex-partner 
Methadone prescription 
Hx Heroin 
Morven 34 Freddie’s partner. 
Older child/ren in kinship care and 
with ex-partner 
Methadone prescription 
Hx Heroin 
Freddie 47 Morven’s partner. 
Older child/ren with ex-partner 
Abstinent 
Hx Heroin 
 
Professional participants and focus groups 
Alongside these interviews, four interdisciplinary focus groups with 27 health and social care 
practitioners were conducted. Focus groups were chosen because they are considered the 
‘method of choice’ when the aim is to explore and examine group interaction, group 
processes, meanings and norms and where consensus and/or debate between participants is 
important (Barbour, 2007). Professionals were invited to take part on the basis of known 
experience working in this area – either with parents who are drug-dependent, their infants or 
both - with care taken to include a mix of community and hospital-based practitioners who 
normally engage with families as part of ‘multi-disciplinary care pathway’. Focus groups 
explored participant’s understandings of NAS, experience of preparing parents for a baby 
with NAS, including monitoring and treatment of mother and baby, and sought to engage 
group members in deliberative discussion and debate about these issues. They were jointly 
conducted by [AC] and [AW] and lasted approximately one hour. 
A profile of the four focus groups is included in Table 3. Of the 27 participants, 21 were NHS 
(healthcare professionals) and 6 were Social Care staff, 23 were female, 4 male, and 
disciplines included: community midwives, postnatal midwives, neonatal nurses, health 
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visitors (community child health nurses), community mental health (addiction) nurses, a 
general medical practitioner (GP), consultant psychiatrist in addictions, consultant 
obstetrician, consultant neonatologist and qualified social workers in community and hospital 
‘Children and Families’ teams and foster care services. Participants also included health and 
social care staff from a community-based specialist pregnancy service for women with 
alcohol and drug problems. 
Table 3: Practitioners in focus groups 
FG01 
Midwife (Community) 
Neonatal Nurse 
Neonatal Nurse 
Addiction Nurse 
Addiction Nurse 
General Practitioner 
Health Visitor 
 
FG02 
Social Worker 
Social Worker 
Midwife (Community) 
Health Visitor 
Addiction Nurse 
Addiction Nurse 
FG03 
Social Worker 
Social Worker 
Early Years Worker 
Addiction Nurse 
Health Visitor 
FG04 
Foster Care Social Worker 
Midwife (Postnatal) 
Midwife (Postnatal) 
Neonatal Nurse 
Health Visitor 
Addiction Nurse 
Neonatologist 
Obstetrician 
Addiction Psychiatrist 
 
 
Data analysis 
Interviews and focus groups were audio-recorded, transcribed verbatim, anonymised, and 
uploaded to NVivo v10 to support data coding and management. Data were coded and 
analysed by [Author1] and [Author2], using inductive content and thematic coding, and 
informed by narrative and discursive approaches - focusing on stories and the construction of 
meaning, subjectivities, representations and performative work. A constant comparative 
method (Silverman, 2014), was then used to compare and contrast discourses and themes 
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across the data sets – for example, differing representations of the NAS baby, mother and 
father, practices in relation to observing and ‘scoring’ the baby and ‘drug testing’ the mother, 
and discourses surrounding ‘medication-assisted’ recovery and the treatment and care of the 
mother and mother-infant dyad. Analytic summaries were discussed and deliberated upon at 
monthly research group meetings and implications of the findings were considered within the 
context of current and alternative models of care.  
 
Findings 
Multiple and contradictory versions of risk and recovery emerged in the accounts of parents 
and professionals. In our analysis we illustrate how these discourses served to both compel 
and trouble all logics of care surrounding NAS - primarily in relation to what might be 
understood, and enacted upon, as forms of ‘accepted knowledge’ and ‘effective interventions’ 
during pregnancy and after the baby is born. For example, ‘risk reduction’ strategies, 
‘monitoring’ and surveillance methods, ‘drug management’, treatment and care of mother 
and baby, and ‘safeguarding’ approaches governing parental caregiving.  
Producing and troubling antenatal logics of care 
Questions about NAS consistently led to discussion and debate regarding the causes of NAS 
and the extent to which maternal drug use during pregnancy (including ‘compliance’ with 
drug treatment plans) played a role in the likelihood of NAS being ‘severe’. 
On the one hand, participant stories about antenatal care served to demonstrate and reiterate 
‘current’ thinking about the causes of NAS, such as why some babies develop severe 
symptoms and others do not. Most professionals, for instance, acknowledged that severity of 
NAS was not directly related to ORT dose or the amount of opioid drugs the mother was 
taking, meaning that the ability to fully predict, and therefore avoid NAS was impossible to 
do. Emphasis instead was placed on the unpredictability of NAS: 
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I think that's one of the hardest things, you can never predict just how badly a baby 
can withdraw. You can look at mum’s drug use and think, this baby is going to be 
really bad and it turns out the opposite. (Neonatal Nurse, FG1) 
 
One mother reiterated a version of this message: 
 
You could be on a really low dose of [opioid] and your baby could have really bad 
symptoms or the other way about. It just kind of, totally depends on the baby itself.  
Everybody’s different. That’s all I’d really been told, just try not to …get too stressed 
about it. (Hayley, mother)  
 
However, accounts also cast doubts about this perceived wisdom by drawing attention to 
contradictory beliefs and practices and other explanatory possibilities. For example, the belief 
that illicit drug use and by inference, the ‘misbehaviour’ or drug-addicted pregnant women, 
might be the real cause of severe neonatal withdrawal symptoms:  
It can be difficult when the baby …does have NAS, for professionals who maybe 
have some limited knowledge to automatically go well, that means she's been taking 
extra drugs during her pregnancy …I've had to explain well, we don't know that. We 
can't then go and write that in [child protection] reports. It could be just, that this is a 
baby that is more susceptible …that's what I've found difficult with a recent case 
…professionals jumping to conclusions and then saying that in front of the parent, 
when the parent's had that information from the Neonatal Unit that actually, there isn't 
a direct correlation. But there's a chance that she was taking extra [drugs] during her 
pregnancy …there's a lot of unknowns, and I suppose when you're planning for the 
future of the baby that's difficult’ (Social Worker, FG2) 
 
This performative work (Fomiatti et al, 2017), served to both uphold and subvert logics of 
care, drawing on the rhetoric of governing risk and ‘risky parents’ (Featherstone et al, 2014). 
In the excerpt above, for example, ‘unknowns’ about maternal drug use could explain 
professionals erroneously ‘jumping to conclusions’ about the cause of NAS being attributable 
to the misbehaviour of drug-addicted mothers when ‘actually, there isn’t a direct correlation’. 
At the same time, ‘unknowns’ about maternal drug use could justify caution when making 
decisions about the future safety and wellbeing of an NAS baby. Conversely, both logics of 
care invite a focus on risk and responsibility (identifying ‘susceptible’ or vulnerable babies 
and unfit mothers who take ‘extra’ drugs) and infer that the cause of NAS is perhaps 
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something that ‘we don’t know’ (despite the ‘Neonatal Unit’ saying otherwise). Introducing 
uncertainty, can be seen as a rhetorical device to construct an array of different subject 
positions and material realities (reckless mother who is to blame for her infant’s poor 
condition or just a predisposed baby whose innocent mother is being unfairly accused of 
neglect). These logics of care obscure however, other ways of representing the baby with 
NAS and responding to the mother-infant dyad – for example, by focusing on meeting the 
care needs of the infant, and providing appropriate family support to facilitate mother-infant 
caregiving. What was foreground in professional accounts was identifying and managing 
(governing) risk, not the meeting of need. Noticeably, it was not simply about clinical ideas 
on cause and effect, since these were contested and contradictory. Rather, professionals were 
speaking to wider social, political and moral positions on working with families affected by 
drug use, including the role of the state in family life. 
Professional accounts which unsettled ideas about whether or not NAS severity was related to 
the mother’s illicit drug-taking behaviour (and therefore whether or not she was ‘to blame’ 
for her infant’s condition) were echoed in parents’ accounts:  
I always thought that the reason the baby was withdrawing [was] because they 
[mothers] were on methadone and using on top [illicit drug use]. (Shelley, mother) 
 
Just luck nae doubt …[but] it probably depends what the mum’s been up to. If the 
mum’s been taking more drugs …most people you speak to [will] lie to you about 
what they’ve taken. (Liam, father) 
  
Parents’ also spoke about their fear of losing custody of the baby if NAS was identified, 
despite feeling that they couldn’t do anything to prevent it. Fear of being blamed for their 
infant’s condition, and self-blame, was accompanied by an acute awareness of the stigma 
associated with maternal drug use, and being judged an unfit mother: 
Before I had [the baby], if somebody said aye, their baby had withdrawed, I’d be like, 
that’s shocking. Why could you no’ get yourself sorted out, and get off the methadone 
and the drugs. But even I did it, so aye …basically people are just this, scummy, 
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basically because their baby’s withdrawing …[but] there’s more issues to it. (Joanne, 
mother) 
 
How I saw it, if the baby’s got NAS you aren’t getting your baby …I was just 
visualising the baby care unit …standing there, my baby screaming, no’ well 
…riddled with guilt, and blaming [partner] …that was my visual …signs of NAS, 
take a count, [NAS score] too high, baby care unit, and that’s that …and very 
judgemental, [like] the way they treated [partner] in the hospital. (Freddie, father) 
 
Representations of mothers who are drug-dependent as liable, or potentially liable, for their 
infant’s ‘vulnerable’ condition, invoked logics of care that centred on risk reduction and risk 
management strategies and elicited narratives which appealed to the value of treatment 
regimens and regulatory practices to ‘assess’ and ‘manage’ these risks. For example, 
‘stability’ on ORT and drug testing pregnant mothers in an attempt to either prove, or 
disprove, illicit drug use:  
Different people have different opinions …I had a patient who appeared stable [on 
methadone], I mean, she was testing negative whenever I took drug screens and her 
baby was very, very, very, unwell …and some professionals have been saying, well 
she was obviously abusing [illicit drugs] then. But, there wasn't any evidence that she 
was. (Addiction Nurse, FG1) 
 
While most participants acknowledged that ORT was an ‘accepted’ treatment during 
pregnancy and would likely benefit mother and baby - for example, through better 
‘engagement’ with services and access to ‘recovery-orientated’ services – ‘stability’ was 
repeatedly emphasised and conflated with better outcomes for the baby in relation to NAS. 
From this perspective, the requirement to remain ‘stable’ became a moral imperative, 
signifying affirmative action to reduce NAS risks. Some parents appealed to these moral 
discourses and conveyed the idea that mothers who ‘chose’ to take illicit drugs, rather than 
comply with OST regimens, ought to be harshly judged (and ashamed of their behaviour):   
So-called friends that have chosen drugs over their children, they know exactly what 
they’re doing …they know their baby’s going to come out rattling [withdrawing] …it 
disgusts me to a certain extent …I’m not one to preach, ‘cause my baby had NAS as 
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well, but we made a choice to stay maintained [on methadone] …to keep her chances 
of it [NAS] being low. (Stuart, father) 
 
I’ve seen with other mums, one [women I know] …still kept dabbling [taking illicit 
drugs], compared to me …like just sticking with methadone, and she’s no’ getting her 
baby home …well it’s in the [neo]natal unit now so it’s like …your baby’s really sick 
even though you knew the risks. (Joanne, mother) 
 
Similarly, professional accounts questioned the extent to which pregnant women who are 
opioid-dependent can ‘control’ their drug use, make ‘lifestyle choices’ and are ‘motivated to 
change’ for the ‘right’ reasons. Shifting positions constructed mothers in contrasting ways - 
for example, as ‘vulnerable’, as untrustworthy, as responsible, and as rational and capable 
actors and decision-makers. The issue of whether mothers could simply ‘decide’ to remain 
‘stable’, or reduce or maintain abstinence (and elect to embark on a ‘recovery journey’), or 
continue to use illicit drugs, was woven into stories about emotional responses to NAS: 
We actually bought a [NAS] withdrawing doll …it’s a real shocker for the women 
…it shakes and it screams, the high pitch scream, and they see it, and it's very visual, 
and it works. I don't know if it totally works for them, to stopping [illicit] drugs … 
[but] two or three [women] every time we do it, start crying, really upset. …It's too 
late obviously, when we show the dolls, but then sometimes it's enough just to say 
right, the rest of the pregnancy, I might abstain from heroin. (Midwife, FG1) 
 
There’s no empathy …people just don't appreciate what these women have been 
through …you know, their upbringing, their life, what’s brought them to this point 
…a lot of staff …think it's a lifestyle choice, they choose to take drugs …but it's not 
as straightforward as that …and if you throw domestic violence in …childhood sexual 
abuse …horrendous things …it's not a lifestyle choice, who would choose that life?, 
nobody does …I don't condone it, but I can understand it. (Neonatal Nurse, FG1) 
 
These accounts served to both support and refute logics of care that either apportioned or 
relinquished individual responsibility for risk-taking behaviour and recovery, and in doing so, 
maintained a focus on maternal ‘risk factors’ rather than other factors which might play a role 
in pregnancy and neonatal outcomes, including quality of care.  
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In fact, few participants articulated the dilemma that most mothers faced: if they followed 
advice to remain ‘stable’ on an optimum ORT dose during pregnancy, they would likely 
benefit from better overall outcomes for themselves and their infant, but they would produce 
a baby ‘at risk’ of NAS. Should their baby then develop symptoms, and be diagnosed an 
‘NAS baby’, they would likely be blamed for the infant’s condition. One father grappled with 
this ‘catch 22’ situation:  
If we knew [the baby] …was going to be twitching, she could have had the 
methadone reduced, but then again …you can’t have the methadone reduced if you 
weren’t stable …it’s a catch 22 she was in, so …I don’t blame her, I blame the [drug 
treatment service]. (Mike, father) 
 
Stories which focused on maternal drug use and ‘the nature of addiction’ (e.g., compliance 
with drug treatment, illicit drug use, recovery and ‘relapse’) invoked logics of care which 
centred on the need to address the mother’s psychopathology (e.g., her ‘motivation’, decision-
making, drug-taking behaviour, poor parenting, trauma, denial etc) and her accountability in 
relation to NAS. Again, contradictory discourses were evident with stories about the need to 
helps mothers with their various psychological and behavioural problems contrasted with the 
need for the mother to simply demonstrate ‘evidence’ of ‘change’ and ‘moving on’. This 
included an emphasis on mothers ‘accepting’ that their baby had NAS (even if symptoms 
were ambiguous) and acknowledging ‘the damage that’s actually been done’.    
[It’s] difficult for parents as well, because if they can’t take responsibility for their 
drug use during pregnancy, I think it can be very hard once baby is born and the guilt 
that they feel, to then help them to start to take some responsibility for that. (Social 
Worker, FG4) 
 
We do get a few woman …that don't acknowledge [the baby has NAS], and they will 
try anything else to say, oh it's feeding problems, it's not to do with NAS, and we do 
try and tell them it is, because it is quite important for them to acknowledge that it is. 
(Midwife, FG1) 
 
Producing and troubling postnatal logics of care 
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Discourses on ‘risk’ and ‘recovery’ relating to the postnatal period centred on two key issues 
which were typically intertwined: the ‘vulnerable’ infant body, potentially suffering from 
severe NAS symptoms, who needed to be closely observed, protected and cared for (by 
competent and responsible adults) and; ‘evidencing’ parenting capacity in relation to the 
‘vulnerable’ baby. This elicited accounts which focused on ‘processes and procedures’ for 
identifying and treating NAS, and scrutinising and evaluating mother-infant caregiving.  
Intensive ‘monitoring’ (e.g., observing and ‘scoring’ the baby, surveillance of the mother) 
were taken for granted aspects of care, as was the need for admission to the Neonatal Unit 
should the infant display NAS symptoms. However, views and experiences of this ‘accepted’ 
model of care were not always consistent or compatible. For example, some parents reported 
feeling marginalised and had no prior knowledge of the ‘NAS score chart’ and little or no 
involvement in ‘scoring’ the baby for symptoms of NAS in the postnatal ward.  
They didn’t even tell me they were doing the test [NAS score] half the time. I just 
knew because …they would fill out the wee thing [NAS chart] in front of you, but 
they never ever let you see it. I had to ask to see it. (Shelley, mother) 
 
I didn’t get like, this is a NAS chart, and this is blah, blah, blah …I didn’t get any of 
that.  …Craig was clueless too about it …and he likes to know everything too. 
(Heather, mother) 
 
For most parents, time in the postnatal ward was characterised as a period of ‘watchful 
waiting’, to see whether their baby would exhibit signs of NAS. Many portrayed their baby as 
vulnerable (e.g. ‘helpless’) and drew on their own embodied experiences of addiction and 
withdrawal, imagining these in the bodies of their baby (‘suffering’, ‘in pain’ and ‘addicted’):  
You don’t know how bad they’re going to be, ‘cause you’ve sort of, withdrawn 
yourself in the past, and you know how bad it can get, you think, God is your baby 
going to be like that. Can they fight it? Will they be alright? (Liz, mother) 
 
You don’t know if it’s [a normal baby crying], or is it rattling? …but it was just a wee 
bit more than that …because you seen it …it was a horrible squeal …you knew [she] 
was in pain …[and] you just want to take if off them, and you can’t. (Ryan, father) 
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I read all about [NAS] …and I just know …[our baby’s] probably nine times more 
likely to become an addict …So, I need to nurture this baby, man …because she was 
born an addict, she’s an addict. We’ll not be able to stop it. (Freddie, father) 
 
Accounts of the scoring process formed part of a logic of care that served to underline the 
view that babies at risk of NAS are not ‘normal’ and drug-using parents are not capable of 
attending to their infants’ needs. Some parents echoed these concerns and revealed how they 
anticipated suspicions (and allegations) about inadequate parenting and engaged in practices 
which might ‘prove’ their innocence:  
I carried on doing her feeding chart [at home] …‘til [baby was] at least three months, 
just in case her weight was to drop again, and we don’t want people to say, well 
you’ve been neglecting your child. I’ll say, well no, ‘cause that’s what she’s been 
eating, so it must be a metabolism problem, so I want her checked out. (Stuart, father) 
 
While some professionals emphasised multiple ‘increased risks’ posed by NAS, others raised 
questions about the whole basis on which NAS, and the care of the family as a whole, was 
represented, and the extent to which existing logics of care address wider issues, including 
broader societal views about maternal drug use:   
[In the neonatal unit] we very rarely see such severe withdrawal symptoms …that put 
the baby’s health at risk, and there’s …no real evidence that it really does …there’s 
no doubt these children have worse outcomes, but …which bit of the package is that 
due to?, whether that’s due to the whole, sort of, messed up lifestyle, antenatal 
consumption of drugs …the diet that goes with it, and then the care that [parents] give 
once the child’s actually home. The withdrawal is only a symptom, if you like, that 
this, sort of, abnormal practice of taking drugs in pregnancy has happened …neonatal 
abstinence is only a little bit of the picture, isn’t it. I don’t think neonatal abstinence in 
itself, is such a big problem. (Medic, FG4) 
 
The most significant tension between participants however, particularly between health and 
social care practitioners, was differing views on the concept of ‘recovery’ (including 
‘medication-assisted recovery) and what this constituted in terms of drug-taking behaviour, 
parenting capacity and child welfare. This tapped into the fundamental question of whether or 
not continued drug use (even if ‘stable’ on ORT) is compatible with ‘good enough’ parenting. 
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For example, ‘medication-assisted recovery’ or ORT, based on a ‘harm reduction’ approach, 
was presented by some as acceptable and indeed desirable for parents and pregnant women, 
whereas reduction in consumption and ‘evidence’ that the mother was ‘working towards 
abstinence’ was presented as essential by others. The following exchange illustrates this 
tension:  
We've got a mum …and she had been using illicit [drugs], she's gone onto a 
methadone prescription, she was only at the beginning stages of being titrated and the 
social worker's demanding to know when she would be having a detox to come 
off!…I just felt like the social worker hadn't obviously had that education …on harm 
reduction …we do set them up to fail because we're asking them to achieve the 
unachievable …[and] we’re going to cause them to relapse. (Addiction Nurse, FG2). 
 
That comes down to social work because we're evidence led, in terms of our 
parenting, because if we have a child at risk of significant harm we're building an 
evidence picture to say …whether the child can remain in that home environment or 
be removed …we're needing evidence of that and that's putting families under quite a 
lot of stress, because they're dealing with the addiction …[and that] can be quite 
difficult, because we're looking at form filling, doing reports, doing risk assessments 
and categorising it …because we ultimately need a journey, and if we're not having a 
journey, well, then the child is left to suffer. (Social Worker, FG2) 
 
These accounts illustrate how contested and contradictory understandings of risk and 
recovery within the context of NAS are closely entwined, and serve to undermine (and 
silence) logics of care, including other, alternative ways of conceptualising, articulating and 
enacting care.  
  
Discussion 
This article has demonstrated how competing discourses on risk and recovery emerge in 
parents’ and professionals’ accounts of NAS. Differing notions of risk and recovery served to 
both compel and trouble all logics of care that govern pregnant women who use drugs and the 
care of the infant and mother-infant dyad in the postnatal period. Representations of NAS 
babies as ‘vulnerable’ and ‘at risk’ – whether actual, suspected or potential – and disputed 
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ideas about what constitutes ‘evidence’ of recovery in pregnant women and mothers who are 
opioid-dependent, served to explain (and justify) risk management strategies that involved 
caution, intervention and control (such as increased scrutiny and surveillance of the bodies of 
babies and mothers). A focus on reducing risks of NAS enrolled parents and professionals 
into practices which served to monitor parental (maternal) drug use. Mothers were required to 
both ’stabilise’ on prescribed opioid therapy and to articulate a desire (if not enact) reduction 
in dosage. At the same time, competing ideas about what recovery might mean, and the 
spectre of ‘recovery as abstinence’, meant that whatever mothers did regarding drug use in 
pregnancy, they were at risk of being viewed unfit and to blame for their infant’s condition.  
The practice of seeking to maintain drug use, or even increase levels of methadone during 
pregnancy in order to minimise harm, rather than aiming to reduce or come off prescription 
drugs, goes to the heart of ideological debates between harm reduction versus abstinence as 
the ultimate goal of drug treatment programmes. This is especially so in relation to pregnant 
women, where the health and wellbeing of the baby is also at stake. The more recent 
translation (and attempted convergence) of these contrasting goals into ‘recovery journeys’ 
and ‘recovery-orientated systems of care’, proposed in many drug and family-focused 
policies (Scottish Government, 2013) denies the real tensions inherent in differing attitudes 
towards ongoing drug use during pregnancy and different drug treatment approaches for 
pregnant women. For example, within the context of pregnancy and parenting, the notion of 
‘medication-assisted recovery’ (Strang, 2012), can jar with child welfare policies which seek 
to promote ‘drug free childhoods’ (U.S. Department of Justice and Education, 2017); and 
studies involving drug-dependent parents demonstrate how the meaning of recovery is 
contested within the context of parenthood (Radcliffe, 2011).   
Our research has significant implications for current practices of care oriented towards 
supporting families whose babies are at risk of NAS. Treatment and care approaches which 
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advocate intensive and intrusive interventions and in-patient care are extremely costly with 
little or no evidence of significant benefit to the baby or mother-infant dyad, either in the 
short or longer-term (Knopf, 2016). Our findings lead us to question the logics of care that 
such approaches entail. We propose a radical rethink in research, policies and practices 
around women who use drugs whereby existing logics of care themselves become the focus 
of inquiry (rather than the bodies of mothers and babies). Instead, we suggest a greater 
emphasis on identification and evaluation of systems where supportive caregiving 
environments for families and strengths-based approaches are possible (instead of a focus on 
parental drug use, deficits, risk and responsibility). This approach would require a shift away 
from the current focus on (addicted) maternal bodies and (vulnerable) neonatal bodies, 
looking more broadly at social, economic, moral, discursive and relational contexts which 
produce and govern such bodies. 
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